Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Junji Furuse

Showing results (11-20 of 348) with videos related to

Pageof 35
Sort By:
Ebiomedicine|February 2, 2019
A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?Junji Furuse
The Lancet. Oncology|February 5, 2010
Targeted therapy for biliary-tract cancerJunji Furuse
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|December 6, 2013
[Current status and future directions of chemotherapy for pancreatic cancer]Junji Furuse
Expert Opinion on Emerging Drugs|March 4, 2017
Emerging protein kinase inhibitors for treating pancreatic cancerJunji Furuse, Fumio Nagashima
Expert Review of Gastroenterology & Hepatology|September 14, 2011
Inhibitor of MEK1/2, selumetinib, for biliary tract cancerJunji Furuse, Fumio Nagashima
Chinese Clinical Oncology|April 6, 2015
Current status and future direction of chemotherapy for pancreatic cancerJunji Furuse, Fumio Nagashima
Journal of Gastroenterology|January 31, 2020
Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelinesTakuji Okusaka, Junji Furuse
Cancers|November 12, 2013
Targeted therapy for biliary tract cancerJunji Furuse, Takuji Okusaka
International Journal of Clinical Oncology|January 31, 2022
Treatments for elderly cancer patients and reforms to social security systems in JapanFumio Nagashima, Junji Furuse
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 3, 2015
[Supportive management of cisplatin and gemcitabine combination therapy for advanced biliary tract cancer]Daisuke Naruge, Junji Furuse
Pageof 35

Showing results (11-20 of 348) with videos related to

Sort By:
Pageof 35
Ebiomedicine|February 2, 2019
A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?Junji Furuse
The Lancet. Oncology|February 5, 2010
Targeted therapy for biliary-tract cancerJunji Furuse
Nihon Shokakibyo Gakkai Zasshi = the Japanese Journal of Gastro-Enterology|December 6, 2013
[Current status and future directions of chemotherapy for pancreatic cancer]Junji Furuse
Expert Opinion on Emerging Drugs|March 4, 2017
Emerging protein kinase inhibitors for treating pancreatic cancerJunji Furuse, Fumio Nagashima
Expert Review of Gastroenterology & Hepatology|September 14, 2011
Inhibitor of MEK1/2, selumetinib, for biliary tract cancerJunji Furuse, Fumio Nagashima
Chinese Clinical Oncology|April 6, 2015
Current status and future direction of chemotherapy for pancreatic cancerJunji Furuse, Fumio Nagashima
Journal of Gastroenterology|January 31, 2020
Recent advances in chemotherapy for pancreatic cancer: evidence from Japan and recommendations in guidelinesTakuji Okusaka, Junji Furuse
Cancers|November 12, 2013
Targeted therapy for biliary tract cancerJunji Furuse, Takuji Okusaka
International Journal of Clinical Oncology|January 31, 2022
Treatments for elderly cancer patients and reforms to social security systems in JapanFumio Nagashima, Junji Furuse
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 3, 2015
[Supportive management of cisplatin and gemcitabine combination therapy for advanced biliary tract cancer]Daisuke Naruge, Junji Furuse
Pageof 35